BRAIN Biotech AG (XTER:BNN) Short-Term Debt & Capital Lease Obligation : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. BRAIN Biotech AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. BRAIN Biotech AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €4.28 Mil.

BRAIN Biotech AG Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for BRAIN Biotech AG's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG Short-Term Debt & Capital Lease Obligation Chart

BRAIN Biotech AG Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

2.64

3.01

4.66

BRAIN Biotech AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															-	-	4.66	-	-

BRAIN Biotech AG Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

BRAIN Biotech AG Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

BRAIN Biotech AG (XTER:BNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

BNN:Germany BNN:Germany BNN:Germany

Address

Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673

Website

https://www.brain-biotech.com

BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.

Executives

Dr. Michael Majerus	Supervisory Board
Dr. Georg Kellinghusen	Supervisory Board
Michael Schneiders	Board of Directors
Adriaan Moelker	Board of Directors
Lukas Linnig	Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines